文献速递肝胆胰外科

合并乙肝肝硬化的富脂型肝细胞癌临床病理特征及预后意义:倾向性评分匹配研究

[Clinicopathological characteristics and prognostic significance of steatotic hepatocellular carcinoma with HBV-related cirrhosis: a propensity score-matched study].
PubMed 文献 · Zhonghua Wai Ke Za Zhi · 2026-01-01

该回顾性队列纳入青岛大学附属医院2014至2020年接受肝切除术并经病理证实为肝细胞癌的689例患者,其中富脂型肝细胞癌(SBC-HCC)占15.5%。经1∶3倾向性评分匹配后分析显示,SBC-HCC组5年总体生存率和无病生存率均低于非SBC-HCC组,且SBC-HCC是总体生存的独立不良预后因素。

要点

  • SBC-HCC占乙肝相关肝细胞癌的15.5%,具有脂质代谢相关临床特征。
  • SBC-HCC组5年OS率69.2%比72.9%、5年DFS率34.4%比44.5%,均低于非SBC-HCC组。
  • SBC-HCC是根治性切除术后OS的独立不良预后因素(HR=1.939)。

核心结论

  • SBC-HCC在乙肝相关肝细胞癌中占一定比例,表现为脂质代谢相关临床特征。
  • SBC-HCC是肝细胞癌根治性切除术后的独立不良预后因素,可作为常规病理评估的补充用于术后风险分层与随访管理。

研究设计与样本

  • 回顾性队列研究,收集2014年1月至2020年12月青岛大学附属医院肝胆胰外科877例肝切除患者资料。
  • 经筛选后689例纳入分析,男性563例(82.1%),女性126例(17.9%),年龄58(13)岁(范围17~85岁)。
  • SBC-HCC定义为数字病理定量评估肿瘤细胞内脂质空泡占比>5%,共107例(15.5%);采用1∶3倾向性评分匹配(卡钳值0.02),匹配后SBC-HCC组79例、非SBC-HCC组237例。

主要发现

  • SBC-HCC组总胆汁酸、总胆固醇、低密度脂蛋白胆固醇及肌酐水平均高于非SBC-HCC组(P值均<0.05)。
  • 随访时间51(34)个月(范围1~139个月);SBC-HCC组中位OS为90.8个月,非SBC-HCC组未达到(P=0.012)。
  • SBC-HCC组5年OS率(69.2%比72.9%)及5年DFS率(34.4%比44.5%)均低于非SBC-HCC组(P值均<0.05)。
  • OS多因素Cox分析:SBC-HCC(HR=1.939,95%CI:1.291~2.913,P<0.01)、肿瘤数量增多(HR=1.694,95%CI:1.321~2.172,P<0.01)、微血管侵犯(HR=1.880,95%CI:1.133~3.122,P=0.015)、肿瘤最大径≥5 cm(HR=3.479,95%CI:2.256~5.364,P<0.01)为独立不良预后因素。
  • DFS多因素Cox分析:LDL-C升高(HR=1.242,95%CI:1.022~1.510,P=0.029)、微血管侵犯(HR=1.866,95%CI:1.251~2.785,P<0.01)、大血管侵犯(HR=2.557,95%CI:1.473~4.439,P<0.01)为独立不良预后因素。

关键数值与推荐

  • SBC-HCC判定标准:数字病理定量评估肿瘤细胞内脂质空泡占比>5%。
  • 匹配方法:1∶3倾向性评分匹配,卡钳值0.02。
  • 亚组分析显示在部分临床和病理学亚组中SBC-HCC提示较差生存结局(P值均<0.05)。

临床怎么用

  • 对肝细胞癌根治性切除标本可行数字病理脂质空泡定量评估,识别SBC-HCC。
  • SBC-HCC患者术后应纳入更密切的随访与风险分层管理。
  • 合并微血管侵犯、大血管侵犯、肿瘤数量增多或肿瘤最大径≥5 cm者预后更差,需加强术后监测。

局限性

  • 本研究为单中心回顾性队列研究。
  • SBC-HCC定义依赖数字病理定量评估,未报告评估一致性等细节。
  • 亚组分析仅报告部分亚组P<0.05,未列出具体亚组数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the clinicopathological characteristics of steatotic hepatocellular carcinoma with HBV-related cirrhosis (SBC-HCC) and its prognostic impact after curative resection. Methods: This is a retrospective cohort study. Data were retrospectively collected from 877 patients who underwent hepatectomy and were postoperatively confirmed as hepatocellular carcinoma (HCC) by pathological examination at Department of Hepatobiliary and Pancreatic Surgery, Qingdao University Affiliated Hospital between January 2014 and December 2020. After screening based on inclusion and exclusion criteria, a total of 689 patients were included in the subsequent analysis. There were 563 male cases (82.1%) and 126 female cases (17.9%); the age (M(IQR)) was 58 (13) years (range: 17 to 85 years). SBC-HCC was defined by digital pathology quantitative assessment as an intratumoral lipid vacuole proportion >5% in tumor cells. Patients were grouped by SBC-HCC status, and 1∶3 propensity score matching (PSM; caliper 0.02) was performed to balance baseline characteristics. Clinicopathological variables, overall survival (OS), and disease-free survival (DFS) were compared between groups. The clinical and pathological characteristics of patients in the two groups were compared using the χ² test, Fisher's exact probability method, independent samples t-test, or Mann-Whitney U test,respectively.Cox proportional hazards models were used to identify independent prognostic factors, and subgroup analyses were conducted. Results: Among the 689 patients, 107 patients (15.5%) were classified as SBC-HCC. After PSM, 79 patients with SBC-HCC and 237 patients without SBC-HCC were included. Major demographic and tumor-related variables were well balanced between groups; however, SBC-HCC patients had higher levels of total bile acids, total cholesterol, low-density lipoprotein cholesterol, and creatinine than non-SBC-HCC patients (all P<0.05). The follow-up time was 51(34) months(range:1 to 139 months). The median OS time was 90.8 months in the SBC-HCC group and was not reached in the non-SBC-HCC group (P=0.012). The SBC-HCC group had significantly lower 5-year OS rate (69.2% vs. 72.9%) and 5-year DFS rate (34.4% vs. 44.5%) than the non-SBC-HCC group (both P<0.05). In multivariable Cox analysis for overall survival, SBC-HCC (HR=1.939, 95%CI: 1.291 to 2.913,P<0.01), increased tumor number (HR=1.694, 95%CI: 1.321 to 2.172, P<0.01), microvascular invasion (HR=1.880, 95%CI: 1.133 to 3.122,P=0.015), and tumor size ≥5 cm (HR=3.479, 95%CI: 2.256 to 5.364, P<0.01) emerged as independent risk factors for poor OS. For DFS, elevated LDL-C (HR=1.242, 95%CI: 1.022 to 1.510, P=0.029), microvascular invasion (HR=1.866, 95%CI: 1.251 to 2.785, P<0.01), and macrovascular invasion (HR=2.557, 95%CI: 1.473 to 4.439,P<0.01) were independently associated with an increased risk of recurrence.Subgroup analyses showed that SBC-HCC was associated with poorer survival outcomes in some clinicopathological subgroups (all P<0.05). Conclusions: SBC-HCC accounts for a non-negligible proportion of HBV-related HCC and is characterized by lipid metabolism-related clinical features. The presence of SBC-HCC is independently associated with worse survival outcomes after curative resection and may serve as a useful adjunct to routine pathological assessment for postoperative risk stratification and follow-up management. 目的: 探讨合并乙肝肝硬化的富脂型肝细胞癌(SBC-HCC)的临床和病理学特征及其对根治性切除术后患者预后的影响。 方法: 本研究为回顾性队列研究。回顾性收集2014年1月至2020年12月于青岛大学附属医院肝胆胰外科接受肝切除术并经术后病理学检查证实为肝细胞癌的877例患者的资料,经纳入及排除标准筛选后,共689例患者纳入后续分析。男性563例(82.1%),女性126例(17.9%);年龄[M(IQR)]58(13)岁(范围:17~85岁)。采用数字病理定量分析方法,将肿瘤细胞内脂质空泡占比>5%定义为SBC-HCC(n=107,15.5%)。以是否为SBC-HCC为分组变量,采用1∶3倾向性评分匹配(PSM)法(卡钳值取0.02)平衡两组患者的基线特征。使用χ²检验、Fisher确切概率法、独立样本t检验或Mann-Whitney U检验比较两组患者的临床和病理学特征,并采用Cox比例风险回归模型分析术后总体生存(OS)及无病生存(DFS)的独立预后因素,同时进行亚组分析。 结果: PSM后,SBC-HCC组79例,非SBC-HCC组237例,两组患者的基线特征基本均衡。SBC-HCC组总胆汁酸、总胆固醇、低密度脂蛋白胆固醇及肌酐水平均高于非SBC-HCC组(P值均<0.05)。全组随访时间51(34)个月(范围:1~139个月)。SBC-HCC组患者的中位OS时间为90.8个月,非SBC-HCC组未达到,差异有统计学意义(P=0.012);SBC-HCC组患者的5年OS率(69.2%比72.9%)及5年DFS率(34.4%比44.5%)均低于非SBC-HCC组(P值均<0.05)。多因素Cox回归分析结果显示,SBC-HCC(HR=1.939,95%CI:1.291~2.913,P<0.01)、肿瘤数量增多(HR=1.694,95%CI:1.321~2.172,P<0.01)、微血管侵犯(HR=1.880,95%CI:1.133~3.122,P=0.015)及肿瘤最大径≥5 cm(HR=3.479,95%CI:2.256~5.364,P<0.01)是肝细胞癌患者OS的独立不良预后因素;LDL-C升高(HR=1.242,95%CI:1.022~1.510,P=0.029)、微血管侵犯(HR=1.866,95%CI:1.251~2.785,P<0.01)及大血管侵犯(HR=2.557,95%CI:1.473~4.439,P<0.01)是肝细胞癌患者DFS的独立不良预后因素。亚组分析结果显示,在部分临床和病理学亚组中,SBC-HCC提示较差的生存结局(P值均<0.05)。 结论: 在肝细胞癌患者中,SBC-HCC具有一定的发生比例,并表现出与脂质代谢相关的临床特征。SBC-HCC是肝细胞癌根治性切除术后的独立不良预后因素,可作为常规病理学评估的补充指标,用于术后风险分层与随访管理。.

来源:Zhonghua Wai Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wei YB, Diao QX, Li ZP, et al. [Clinicopathological characteristics and prognostic significance of steatotic hepatocellular carcinoma with HBV-related cirrhosis: a propensity score-matched study]. Zhonghua Wai Ke Za Zhi. 2026. PMID: 42056062. doi:10.3760/cma.j.cn112139-20260204-00056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。